Sunteți pe pagina 1din 15

AIM: To prepare and evaluate immediate release tablet containing high dose and

low dose of API and to study effect on dissolution rate and content uniformity.
a. Tablet of Aspirin of high dose
b. Tablet of Aspirin of low dose

FORMULA:
( a) Each tablet contains Aspirin = 300mg
Excipients
(b)

= q.s.

Each tablet contains Aspirin = 25mg


Excipients

= q.s.

Batch size = 50 tablets


Packaging = Aluminium strip or Polypropylene strip of 10 tablets
FORMULATION:

( a) For high dose drug:


INGREDIENTS

Aspirin
Starch
Starch paste
Lactose
DCP
Talc
Mg stearate
Aerosil

QUANTITY
GIVEN
300mg
15.8mg
q.s
15.8mg
13.8mg
8mg
4mg
0.148mg

QUANTITY
TAKEN
15g
0.79g
q.s
0.79g
0.69g
0.4g
0.2g
.074g

ROLE OF
INGREDIENT
S
Analgesic
Diluent
Binder
Diluent
Disintegrant
Lubricant
Glidant
Glidant

(b) For low dose drug


INGREDIENTS

Aspirin
Starch
Starch paste
Lactose
DCP
Talc
Mg stearate
Aerosil

QUANTITY
GIVEN

QUANTITY
TAKEN

25mg
290.8mg
q.s
15.8mg
13.8mg
8mg
4mg
0.148mg

1.2g
14.5g
q.s
0.79g
0.69g
0.40g
0.2g
0.074g

ROLE OF
INGREDIENT
S
Analgesic
Diluent
Binder
Diluent
Disintegrant
Lubricant
Glidant
Glidant

PROCEDURE:
METHOD OF PREPARATION:
All the ingredients were weighed accurately.
Aspirin, starch powder, lactose, DCP, were taken in mortar nd pestle and
grinded together to have uniform mixing nd obtain fine powder.
10% of starch paste was prepared and q.s was added to the fine powder to
obtain the lump mass.
This lump mass was then passed through 10# sieve to obtain granules and
were allowed to dry in oven at 60C.
Granules were then passed through 20# sieve and retained on 40# sieve.
Fines obtained were weighed.
15% of fines were added to the dried granules and pack edt in zip lock bag
and punched into tablets using tablet punching machine.

Tablets were then evaluated.

METHOD OF CHARACTERIZTION:

Micromeritical Properties of granules:


i. Carrs Index
ii. Hausners ratio

iii.

Angle of repose
Hardness
Friability
Dissolution study:
Weight Variation
Assay procedure:
20 tablets were weighed and powdered.
A quantity of powder was weighed accurately containing about 0.5g of
Aspirin and 30 ml of 0.5M NaOH was added.
It was boiled gently for 10 mins.
The excess of alkali was cooled and titrated with 0.5M HCl using phenol red
as an indicator.
The operation was repeated without the substance under examination.
The difference between the titrations represents the amount of NaOH
required.

FACTOR:
1ml of 0.5M NaOH is equivalent to 0.04504g of Aspirin

LIMITS:
NLT 95% and NMT 105% of stated amount of Aspirin should be present.

OBSEVATION TABLE:
WEIGHT VARIATION:
Sr No.

Weight of tablets

Assay
BURETTE
READING
BLANK
BACK
DIFFERENCE

Calculation:

FOR HIGH
DOSE

FOR LOW DOSE

1) Dissolution study:
For high dose:
SR TIME ABSORBAN
NO
C

CONC.
(Gm/100ml
)

CONC.
(mg/100ml
)

CONC.
(mg/900ml
)

%CPR

For low dose:


SR TIME ABSORBAN
NO
C

CONC.
(Gm/100ml
)

CONC.
(mg/100ml
)

CONC.
(mg/900ml
)

%CPR

COMMENT:
1. In case of high dose formulation the physicochemical characteristics of
API determines the formulation characteristics. If API is poorly flowable
and poorly wettable it should be made hydrophilic by wet granulation
method. If API is having good flow and hydrophilicity it can be
formulated by direct compression.
2. The formulation containing low dose/ potent API the excipient
determines the formulation characteristics so excipient which provides
good flow and compressibility should be used for preparation. Incase of
low dose formulation the blend uniformity is very important to ensure
content uniformity so geometric mixing is advisable.
3. In present study the effect of dose of API on the key parameters like
content uniformity and dissolution rate is investigated.
4. The observation shows that

AIM:
REQUIREMENTS: Antacid marketed preparation, pH strip, viscometer,
slide, coverslip, dropper, microscope.

REFERENCE:

MARKETED FORMULATIONS:

1. ABIGEL SUSPENSION:
Content: Aluminium Hydroxide - 250mg
Magnesium Hydroxide - 250mg
Simethicone
- 25mg
Volume: 170ml
Price:
49.95/Company Name: Alpic Biotech

2. GELUSIL MPS SUSPENSION:


Content: Dimethicone I.P 50mg
Magnesium Hydroxide I.P 250mg
Dried Aluminium Hydroxide Gel 250mg
Sorbitol Solution I.P(70%) 1.25g
Volume:170 ml
Company Name: Pfizer

3. ULGEL ORAL SUSPENSION:


Content: Magaldrate 400mg
Simethicone 20 mg
Volume: 170ml
Price:

45.50/-

Company Name: Alembic

PROCEDURE:
All the marketed preparations were collected and evaluated using different
parameters

EVALUATION PARAMETERS:
Organoleptic Characteristics
Colour
Odour
Taste/Flavor
Particle Size Distribution
Redispersibility
Sedimentation Volume Ratio
pH value
Viscosity

OBSERVATION TABLE:
1. Particle Size Distribution:
Calibration Factor:
No. of divisions of stage micrometer= 10(y)
No. of divisions of eye piece micrometer=7.1(x)
(y/x)*10= 10/7.1*10
= 14.08m

FORMULATION
GELUSIL

TOTAL
ULGEL

TOTAL

RANGE

MEAN(d)

NO. OF
PARTICLES(f)

f*d

Sedimentation Volume Ratio:


FORMULATIO
N
GELUSIL

ULGEL

FORMULATION
GELUSIL

ULGEL

TIME(MINS)

H0

HU

SVR

0
10
20
30
40
50
60
0
10
20
30
40
50
60
EVALUATION
PARAMETER
Colour
Odour
Flavor
pH
viscosity
No.of inversions
Colour
Odour
Flavor
pH
No.of inversions
viscosity

OBSERVATION

AIM:
REQUIREMENTS: pH strip, viscometer, slide, coverslip, dropper,
microscope, Marketed oral emulsions.

REFRENCE:

MARKETED FORMULATIONS:
1. CREMAFFIN:
Content:
Milk Of Magnesia: 11.25ml
Liquid Paraffin: 3.75ml
Volume: 170ml
Price: 57/Company Name: Abott

2. DUALAXIN:
Content:
Liquid Paraffin: 1.25ml
Magnesium Hydroxide: 3.75/15ml
Volume: 200ml
Price: 62.3/Company Name: Glenmark

3. ACMEFFIN:
Content:
Liquid Paraffin: 3.75ml
Volume: 170ml
Price: 62/Company Name: Acme

PROCEDURE:

All the marketed preparations were collected and evaluated


using different parameters.

EVALUATION PARAMETERS:
Organoleptic Characteristics
Colour
Odour
Taste/Flavor
Globule size
Type of Emulsion
Stability (Cracking, Creaming, Phase inversion)
pH value
Viscosity
Methods for Determination Of Type Of Emulsion:
Dilution Test
Dye test
Flouresence
Conductivity

OBSERVATION TABLE:
FORMULATION

RANGE

MEAN
(d)

NO. OF
GLOBULES(f)

CREMAFFIN

TOTAL
DUOLAXIN

TOTAL

FORMULATION

EVALUATION
PARAMETERS

OBSERVATION

f*d

CREMAFFIN

DUOLAXIN

Colour
Odour
Taste/Flavor
Type of emulsion
Viscosity
pH
Stability
Colour
Odour
Taste/Flavor
Type of emulsion
Viscosity
pH
Stability

S-ar putea să vă placă și